Amongst n = 59 patients with obesity, chronic kidney disease and type 2 diabetes, 2 (3.5%) and 0 (0%) were prescribed a GLP‐1 receptor analogue and SGLT2‐inhibitor, respectively. This evidence concerns the gene SLC5A2 and chronic kidney disease.